Gynoflor (Estriol, Lactobacillus Acidophilus)

Gynoflor is indicated for conditions related to estrogen deficiency in the vaginal tissue and for supporting a healthy microbial environment.

• Treatment of vaginal atrophy caused by menopause or other estrogen‑deficient states.
• Relief of dyspareunia (painful intercourse) associated with vaginal dryness.
• Management of chronic vaginal dryness and irritation.
• Restoration and maintenance of normal Lactobacillus‑dominant vaginal flora.
• Adjunct therapy after antibiotic treatment for bacterial vaginosis.

Local application of Gynoflor may produce a range of effects, most of which are mild and resolve without intervention.

Common

• Mild vaginal irritation or burning sensation.
• Increased vaginal discharge that is clear or whitish.
• Spotting or light vaginal bleeding, especially during initial use.
• Temporary increase in urinary frequency.

Serious

• Severe allergic reaction with swelling of the vulva, itching, or rash.
• Persistent or heavy vaginal bleeding.
• Signs of estrogen‑dependent tumor growth (rare).

Before prescribing Gynoflor, clinicians should evaluate patient history and consider specific safety factors.

• Not recommended for women with known hypersensitivity to estriol or Lactobacillus species.
• Caution in patients with a history of estrogen‑dependent cancers (e.g., breast, endometrial).
• Use with care in individuals with unexplained vaginal bleeding.
• Avoid in active thromboembolic disorders or severe liver disease.
• Discuss potential risks with pregnant or breastfeeding women; safety data are limited.
• Monitor for signs of infection if used after antibiotic therapy.

Gynoflor can interact with systemic medications or other vaginal products, influencing efficacy or safety.

Avoid

• Concurrent use of systemic estrogen therapy (may increase overall estrogen exposure).
• Use with other vaginal hormonal preparations (risk of excess estrogen).

Use with caution

• Antifungal or antibacterial vaginal agents (may affect probiotic viability).
• Hormonal contraceptives containing estrogen (monitor for additive effects).
• Medications that influence coagulation (e.g., oral anticoagulants) – monitor bleeding risk.